. 2020 Oct 7;190(3):365–375. doi: 10.1093/aje/kwaa210

Table 3.

Counts and Annualized Rates for Outcomes in the Women’s Health Initiative Estrogen + Progestin Trial Among Postmenopausal Women Enrolled in 1993–1998 at Ages 50–79 Years Across 40 Clinical Centers, United States, With Cumulative Follow-up Through 2016

	Subgroup Aged 50–59 Years (n = 5,520)				Trial of CEE + MPA (n = 16,608)
Outcomes	CEE + MPA (n = 2,837)		Placebo (n = 2,683)		CEE + MPA (n = 8,506)		Placebo (n = 8,102)
	No.	%	No	%	No.	%	No	%
Intervention Phase
Primary outcomes
Coronary heart disease	38	0.23	27	0.17	196	0.41	159	0.35
Invasive breast cancer	55	0.33	42	0.27	205	0.43	155	0.35
Other monitored outcomes
Stroke	26	0.15	16	0.10	159	0.33	110	0.24
Pulmonary embolism	18	0.11	8	0.051	87	0.18	41	0.091
Colorectal cancer	7	0.041	8	0.051	50	0.10	76	0.17
Endometrial cancer	6	0.035	5	0.032	27	0.056	30	0.066
Hip fracture	1	0.006	5	0.032	53	0.11	75	0.17
All-cause mortality^a	35	0.21	48	0.31	250	0.52	238	0.53
Global indices
Univariate	170	1.03	141	0.91	875	1.88	737	1.68
Multivariate	186	1.10	159	1.01	1,027	2.13	884	1.96
Cumulative Follow-up
Primary outcomes
Coronary heart disease	129	0.28	114	0.26	710	0.55	652	0.53
Invasive breast cancer	198	0.43	136	0.31	574	0.45	432	0.36
Other monitored outcomes
Stroke	87	0.19	77	0.17	579	0.45	492	0.40
Pulmonary embolism	55	0.12	48	0.11	235	0.18	199	0.16
Colorectal cancer	44	0.094	35	0.079	178	0.14	197	0.16
Endometrial cancer	39	0.083	47	0.11	97	0.74	127	0.10
Hip fracture	43	0.091	48	0.11	394	0.30	421	0.34
All-cause mortality^a	266	0.56	267	0.60	1870	1.42	1793	1.44
Global indices
Univariate	673	1.55	612	1.47	3,265	2.78	3,009	2.67
Multivariate	861	1.82	772	1.74	4,637	3.52	4,313	3.45

Abbreviations: CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate.

^a For consistency with other monitored outcomes included in the global index, extended follow-up includes only participants who provided consent for long-term follow-up.